Companies in #Colorectal Cancer

Firefly Bio is a clinical-stage bioconjugate and antibody-drug conjugate (ADC) company leveraging chemistry pioneered by Nobel laureate Carolyn Bertozzi to develop next-generation ADCs targeting KRAS-mutant and other solid tumors. Its lead programs combine site-specific bioconjugation with tumor-selective payload chemistries designed to widen the therapeutic index versus first-generation ADC platforms.

Imunon is a clinical-stage biotechnology company developing DNA-mediated immunotherapies and vaccines based on two non-viral delivery platforms, TheraPlas for coding proteins and cytokines and PlaCCine for coding viral antigens. Its lead programme is IMNN-001, a DNA-based immunotherapy encoding interleukin-12 that is in a Phase 3 trial for the localised treatment of advanced ovarian cancer, with IND-enabling work in colorectal and pancreatic cancer and discovery work in glioblastoma. A second programme, IMNN-101, is a COVID-19 booster vaccine that has completed Phase 1. The company was incorporated in 1982, was formerly known as Celsion Corporation, and took its current name in September 2022; it is headquartered in Lawrenceville, New Jersey and employs roughly 20 people. In September 2026 Imunon converted $1.2 million of debt to equity, lowering the outstanding balance of the original note by about 43% without issuing common stock or dilutive warrants.

Nouscom is a clinical-stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines on a proprietary viral-vector platform, including the NOUS-209 program in Lynch syndrome and neoantigen vaccines encoding hundreds of tumor-specific antigens. It operates from Basel, Switzerland and Rome, Italy.